All In Biotech

Drug Trial Radar · NCT00772928

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Immunogenicity Assessment of Pentacel™ (Hybrid CP20/20/5/3DT-mIPV//PRP-T) When Given at Different Times From or Concurrently With a Pneumococcal Conjugate Vaccine

Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,167 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,167

Actual

Start

Oct 2003

Primary completion

May 2006

Study completion Nov 2006

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.

Conditions

  • Diphtheria
  • Tetanus
  • Haemophilus Infection
  • Pertussis
  • Polio

Interventions

  • Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®Biological

    0.5 mL, Intramuscular

  • Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®Biological

    0.5 mL, Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With 4-fold Rises in Levels of Pentacel™ Vaccine Antibody Titers Post-dose 3 When Given at Different Times or Concurrently With a Pneumococcal Conjugate Vaccine (Prevnar®)Time frame: 28 to 48 days post-3rd vaccination
  2. Geometric Mean Titers of Antibodies to Pertussis, Diphtheria, Tetanus, Polyribosylribitol Phosphate and Poliovirus Elicited by an Infant Series of Pentacel™ When Given at Different Times or Concurrently With a Pneumococcal Conjugate Vaccine (Prevnar®)Time frame: 60 Days Post-dose 3

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Montgomery, Alabama

  • Site not named

    Fayetteville, Arkansas

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fountain Valley, California

  • Site not named

    Oakland, California

  • Site not named

    Rolling Hills Estate, California

  • Site not named

    Norwich, Connecticut

  • Site not named

    Bardstown, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Kansas City, Missouri

  • Site not named

    Brooklyn, New York

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Austin, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Layton, Utah

  • Site not named

    Spokane, Washington

  • Site not named

    Vancouver, Washington

  • Site not named

    La Crosse, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.